

# Health statistics

Atlas on mortality in the **European Union** 

**Chapter 13 Breast cancers** 

Data 1994-96









Europe Direct is a service to help you find answers to your questions about the European Union

New freephone number: 00 800 6 7 8 9 10 11

A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int).

Luxembourg: Office for Official Publications of the European Communities, 2002


ISBN 92-894-3727-8

© European Communities, 2002

### ATLAS — Contents

1.	Introduction	9
2.	Methodology	11
3.	General mortality	15
4.	'Premature' mortality	23
5.	Mortality by age group	27
6.	Typologies of mortality by age	43
7.	Typologies of mortality by cause	49
8.	Cardiovascular diseases	53
9.	Respiratory diseases	59
10.	Respiratory cancers	65
11.	Intestinal cancers (colon, rectum and anus)	71
12.	Stomach cancers	75
13.	Breast cancers	79
14.	Cancers of the uterus.	81
15.	Prostate cancer	83
16.	Cancer of the pancreas	85
17.	Cancer of the bladder	89
18.	Malignant melanoma of the skin	93
19.	Mortality associated with alcoholism	97
20.	Violent deaths	101
21.	AIDS	111
Anr	nex 1 — Standard European population	115 116





#### 13. Breast cancers

Breast cancer is the most common type of cancer to affect women. It accounts for over 4 % of deaths among the female population of Europe and often affects young women: over half the number of deaths occur before 65 years. This pathology is the main cause of mortality in women aged between 45 and 64 (over 12 % of deaths).

Although there are clear-cut differences in the geographical pattern of female mortality from breast cancer, it should be noted that the differences in mortality across Europe are considerably less pronounced than other cancers, particularly cancers of the respiratory tract or the upper aero-digestive tract. The range of mortality compared with that of these cancers is small, at a ratio of 1 to 2.6.


#### A clear-cut geographical pattern

The regional maps showing the incidence of breast cancer, which is similar at all ages and before 65 years, reveals that the spatial distribution of rates is not random and that there are continuities.

A broad band of excess mortality comprises Denmark, with the highest rates in Europe, Belgium, western Germany, north-west France, northern Italy, Luxembourg, the Netherlands, Austria and the UK.

In the rest of the EU, the rates are considerably lower, particularly in Greece, Spain, Finland and Sweden.

In Portugal, there is a clear north/south divide, with the northern regions more favourably placed. The Mediterranean islands of Corsica, Sardinia, Sicily and the Balearics (but not the Greek islands) have 80



similar fairly high rates, so that they are not as well placed as their respective countries.

Apart from Germany, France, Italy and Portugal, where there are marked regional contrasts, the distribution of mortality from breast cancer is determined, on the whole, by national trends.

## Breast cancer is caused by a number of factors

A number of risk factors are recognised as conducive to the development of breast cancer, and the geographical distribution of these cancers probably reflects an uneven spatial distribution of these risk factors.

Hormonal factors are often mentioned. It is maintained that early menarche, late age at first birth;

nulliparity and late menopause increase the risk of breast cancer, while breastfeeding plays a protective role. Excessive consumption of fat is also said to increase the risk of cancer, while the consumption of fresh fruit and green vegetables is said to reduce it. Genetic factors are also claimed to increase the risk of cancer, although less frequently.

These factors may explain the variations in the incidence of cancer but not so much mortality itself, since there is a 10-year survival rate of approximately 50 % for breast cancer. However, the seriousness of the prognosis depends mainly on how early the diagnosis is made. The differences in mortality in the EU should thus be seen in the light of the specific national screening policies.